natgillin/translations-raw huggingface dataset:
The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (≤18 years of age) than in adults.
Med neželenimi učinki, poročanimi v postmarketinških raziskavah, se pri otrocih in mladostnikih (starih 18 let) v primerjavi z odraslimi bolniki, relativno pogosteje pojavljajo reakcije na mestu injiciranja (bolečina na mestu injiciranja, reakcija na injekcijskem mestu) in kožne reakcije (srbenje, urtikarija).
The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (≤18 years of age) than in adults.
Med neželenimi učinki, poročanimi v postmarketinških raziskavah, se pri otrocih in mladostnikih (starih 18 let) v primerjavi z odraslimi, relativno pogosteje pojavljajo reakcije na injekcijskem mestu (bolečina na mestu injiciranja, reakcija na mestu injiciranja) in kožne reakcije (srbenje, urtikarija).
The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (≤18 years of age) than in adults.
Med neželenimi učinki, poročanimi v postmarketinških raziskavah, se pri otrocih in mladostnikoh (starih 18 let) v primerjavi z odraslimi bolniki, relativno pogosteje pojavljajo reakcije na mestu injiciranja (bolečina na mestu injiciranja, reakcija na mestu injiciranja) in kožne reakcije (srbenje, urtikarija).
The adverse reactions (all grades) experienced by at least 20% of the patients in renal cell carcinoma and mantle cell lymphoma registration studies include anaemia, nausea, rash (including rash, pruritic rash, maculopapular rash, pustular rash), decreased appetite, oedema asthenia, fatigue, thrombocytopaenia, diarrhoea, pyrexia, epistaxis, mucosal inflammation, stomatitis, vomiting, hyperglycemia, hypercholesterolemia, dysgeusia, pruritus, cough, infection, pneumonia, dyspnoea.
Neželeni učinki (vseh stopenj), ki so se pojavili pri vsaj 20 % bolnikov, ki so sodelovali v registracijskih preskušanjih pri karcinomu ledvičnih celic in limfomu plaščnih celic, vključujejo anemijo, navzeo, izpuščaje (vključno z izpuščajem, srbečim izpuščajem, makulopapuloznim izpuščajem, pustuloznim izpuščajem), zmanjšanje apetita, edeme, astenijo, utrujenost, trombocitopenijo, diarejo, pireksijo, epistakso, vnetje sluznice, stomatitis, bruhanje, hiperglikemijo, hiperholesterolemijo, disgevzijo, pruritus, kašelj, okužbe, pljučnico, dispnejo.
The adverse reactions are classified as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni kot: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000)in ni znana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
The adverse reactions are classified by System Organ Class and frequency, using the following convention: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni po organskih sistemih in po pogostnosti z upoštevanjem naslednjega dogovora: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The adverse reactions are displayed by system organ class and frequency: very common (≥1/10), common (≥1/100 to < 1/10), uncommon (≥1/1000 to < 1/100), rare (≥1/10,000 to < 1/1000) and very rare (< 1/10,000).
Neželeni učinki so navedeni po organskem sistemu in pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1 000 do < 1/100), redki (≥ 1/10 000 do < 1/1 000), zelo redki (< 1/10 000).
The adverse reactions are listed below by system organ class and absolute frequency.
Neželeni učinki, , so navedeni po organskih sistemih in absolutni pogostnosti.
The adverse reactions are listed below by system organ class and absolute frequency.
Neželeni učinki, ki jih smatrajo za vsaj morda povezane z zdravljenjem, so navedeni spodaj po razvrstitvi organskih sistemov in absolutni pogostnosti.
The adverse reactions are listed below, by system organ class and by frequency.
Neželeni učinki so navedeni spodaj glede na organski sistem in pogostost.
The adverse reactions are listed by system organ class and frequency using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to
Neželeni učinki so navedeni po organskih sistemih in pogostnosti po naslednjem dogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do
The adverse reactions are listed by system organ class and frequency: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and not known (cannot be estimated from the available data).
Neželeni učinki so našteti po organskem sistemu in pogostnosti: zelo pogosti (≥ 1/10), pogosti (od ≥ 1/100 do < 1/10), občasni (od ≥ 1/1.000 do < 1/100) in neznana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
The adverse reactions are listed by system organ class, frequency category and grade of severity.
Neželeni učinki so našteti po organskih sistemih, pogostnosti pojavljanja in stopnji izraženosti.
The adverse reactions associated with the use of teriparatide in osteoporosis clinical trials and post- marketing exposure are summarised in the table below.
Neželeni učinki, povezani z uporabo teriparatida pri bolnikih z osteoporozo v kliničnih preskušanjih in pri izpostavljenosti po prihodu zdravila na trg, so povzeti v spodnji preglednici.
The adverse reactions considered at least possibly related to the treatment are listed below by body system, organ class and absolute frequency.
V nadaljevanju navajamo neželene učinke, za katere obstaja vsaj najmanjša možnost, da so povezani z zdravljenjem s to učinkovino; razvrščeni so po telesnih sistemih, organih in po absolutni pogostnosti.
The adverse reactions considered at least possibly related to treatment from clinical study and post- marketing experience are listed below by body system organ class and frequency.
Neželeni učinki, za katere se na podlagi kliničnih študij in izkušenj med trženjem meni, da obstaja vsaj možna povezanost z zdravljenjem, so navedeni spodaj glede na organske sisteme in pogostnost.
The adverse reactions considered at least possibly related to treatment with NUEDEXTA in the placebo-controlled and the open-label extension phase of the above mentioned clinical study are listed below by body system organ class and frequency. very common (≥1/10)
Neželeni učinki, ki so bili v s placebom nadzorovani in odprti podaljšani fazi zgoraj omenjene študije vsaj morebitno povezani z zdravljenjem z zdravilom NUEDEXTA, so navedeni spodaj glede na organski sistem in pogostnost. zelo pogosti (≥1/10);
The adverse reactions considered at least possibly related to treatment with the components of emtricitabine/tenofovir disoproxil from clinical study and post-marketing experience in HIV-1 infected patients are listed in Table 3, below, by body system organ class and frequency.
Spodaj v preglednici 3 so po organskih sistemih in pogostnosti navedeni neželeni učinki, ki so vsaj možno povezani z zdravljenjem z učinkovinami emtricitabin / dizoproksiltenofovirat na podlagi kliničnih preskušanj in izkušenj v obdobju trženja zdravila pri bolnikih, okuženih s HIV–1.
The adverse reactions considered at least possibly related to treatment with the components of Truvada from clinical study and post-marketing experience in HIV-1 infected patients are listed in Table 3, below, by body system organ class and frequency.
Spodaj v preglednici 3 so po organskih sistemih in pogostnosti navedeni neželeni učinki, ki so vsaj možno povezani z zdravljenjem z učinkovinami zdravila Truvada pri bolnikih s HIV–1 na podlagi kliničnih študij in izkušenj po prihodu zdravila na tržišče.
The adverse reactions considered to be possibly or probably related to the administration of docetaxel have been obtained in:
Podatki o neželenih učinkih, ki so morda ali verjetno povezani z uporabo zdravila docetaksel, so bili zbrani pri:
The adverse reactions described in the Toxicology and Reproduction toxicity sections below were not observed in clinical studies, but were seen in animals at exposure levels similar to clinical exposure levels.
Neželenih učinkov, opisanih v spodnjih poglavjih Toksikologija in Vpliv na sposobnost razmnoževanja, v kliničnih študijah niso opazili, vendar so jih opazili pri živalih s podobnimi ravnmi izpostavljenosti kot so ravni klinične izpostavljenosti.
The adverse reactions described in this section were identified in the pivotal clinical study (N = 189).
Neželene učinke, opisane v tem poglavju, so ugotovili v ključni klinični študiji (n = 189).
The adverse reactions have been included in the table as a result of postmarketing or clinical study data from the use of tadalafil in the treatment of erectile dysfunction.
Neželeni učinki so bili vključeni v tabelo kot posledica podatkov iz obdobja trženja ali podatkov iz kliničnih študij o uporabi tadafila za zdravljenje erektilne disfunkcije.
The adverse reactions identified in these clinical trials and from post-marketing experience are presented in table 1.
Neželeni učinki, ugotovljeni v teh kliničnih preskušanjih in med obdobjem trženja zdravila, so prikazani v tabeli 1.
The adverse reactions in Study D2302 (TRANSFORMS), a 1-year study in 849 patients treated with fingolimod which used interferon beta-1a as comparator, were generally similar to placebo-controlled studies, taking into account the differences in study duration.
V študiji D2302 (TRANSFORMS), enoletni študiji z 849 bolniki, ki so prejemali fingolimod, v kateri je bilo primerjalno zdravilo interferon beta-1a, so bili neželeni učinki večinoma podobni kot v obeh študijah, kontroliranih s placebom, ob upoštevanju razlike v trajanju posamezne študije.
The adverse reactions in the adult ITP studies (N=550), paediatric ITP studies (N=107), the HCV studies (N=955), the SAA studies (N=43) and post-marketing reports are listed below by MedDRA system organ class and by frequency.
Neželeni učinki iz študij pri odraslih bolnikih z ITP (N = 550), študij pri pediatričnih bolnikih z ITP (N = 107), HCV študij (N = 955), študij hude aplastične anemije (N = 43) in poročil po prihodu zdravila na trg so v nadaljevanju navedeni po MedDRA podatkovni bazi glede na organske sisteme in pogostnost.
The adverse reactions listed below have been accumulated from controlled clinical trials in patients treated for hypertension and from post-marketing reports.
Spodaj našteti neželeni učinki so bili zbrani iz vseh kliničnih preskušanj z bolniki, ki so se s telmisartanom zdravili zaradi hipertenzije, ali z bolniki in iz poročil po začetku trženja.
The adverse reactions listed below have been accumulated from controlled clinical trials in patients treated with telmisartan for hypertension and from post-marketing reports.
Spodaj našteti neželeni učinki so bili zbrani iz vseh kliničnih preskušanj z bolniki, ki so se s telmisartanom zdravili zaradi hipertenzije in iz poročil po začetku trženja.
The adverse reactions listed below in table 1 are classified according to System organ class.
Neželeni učinki so opredeljeni spodaj v preglednici 1 glede na organske sisteme.
The adverse reactions listed in the table below were reported in at least one of the 321 patients receiving delamanid in the double blind placebo controlled clinical trial mentioned above.
O navedenih neželenih učinkih v spodnji tabeli so poročali pri vsaj enem od 321 bolnikov, ki so prejemali delamanid v dvojno slepem, s placebom nadzorovanem kliničnem preskušanju navedenem zgoraj.
The adverse reactions listed in this section are primarily derived from clinical trials and/or as adverse drug reactions from spontaneous reports when ribavirin was used in combination with interferon alfa- 2b or peginterferon alfa-2b.
Neželeni učinki, navedeni v tem poglavju, izvirajo v prvi vrsti iz kliničnih preskušanj in/ali spontano poročanih neželenih učinkov, ko je bil ribavirin uporabljen v kombinaciji z interferonom alfa-2b ali peginterferonom alfa-2b.
The adverse reactions listed in this section fall into the following frequency categories: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
V tem poglavju so neželeni učinki navedeni po pogostnosti na naslednji način: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), ni znano (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
The adverse reactions most commonly (≥1% in the total perampanel group and greater than placebo) leading to discontinuation were dizziness and somnolence.
Neželena učinka, ki sta najpogosteje (≥ 1 % v celotni skupini, ki je prejemala perampanel, in več kot pri placebu) povzročila prekinitev, sta bila omotica in zaspanost.
The adverse reactions observed for the combination of dolutegravir + abacavir/lamivudine in an analysis of pooled data from Phase IIb to Phase IIIb clinical trials were generally consistent with the adverse reaction profiles for the individual components dolutegravir, abacavir and lamivudine.
Neželeni učinki, zabeleženi pri kombinaciji dolutegravirja + abakavirja/lamivudina v analizi zbranih podatkov iz kliničnih preskušanj faze IIb do IIIb, so bili na splošno skladni s profili neželenih učinkov posameznih komponent: dolutegravirja, abakavirja in lamivudina.
The adverse reactions observed in adolescent patients who received treatment with tenofovir disoproxil fumarate were consistent with those observed in clinical studies of tenofovir disoproxil fumarate in adults (see section 4.8 Tabulated summary of adverse reactions and 5.1).
Neželeni učinki, ki so jih opazili pri mladostnikih, ki so se zdravili z dizoproksiltenofovirijevim fumaratom so bili v skladu s tistimi, ki so jih opazili v kliničnih študijah z dizoproksiltenofovirijevim fumaratom pri odraslih (glejte poglavji 4.8 Povzetek neželenih učinkov, prikazan v preglednici in 5.1).
The adverse reactions observed in adolescents are similar to the ones observed in adults.
Neželeni učinki, ki so jih opazili pri mladostnikih so podobni tistim, ki so jih opazili pri odraslih.
The adverse reactions observed in clinical studies and reported in post-marketing experience are detailed below.
Neželeni učinki, opaženi v teh kliničnih študijah in opisani med uporabo v obdobju trženja zdravila, so natančno navedeni spodaj.
The adverse reactions observed in clinical studies and reported in post-marketing experience are detailed below.
Neželeni učinki, opaženi v teh kliničnih študijah in opisani med uporabo v obdobju trženja zdravila, so podrobno navedeni spodaj.
The adverse reactions observed in paediatric patients who received treatment with tenofovir disoproxil fumarate were consistent with those observed in clinical studies of tenofovir disoproxil fumarate in adults (see section 4.8 Tabulated summary of adverse reactions and 5.1).
Neželeni učinki, ki so jih opazili pri pediatričnih bolnikih, zdravljenih z dizoproksiltenofovirijevim fumaratom, so bili v skladu s tistimi, ki so jih opazili v kliničnih študijah z dizoproksiltenofovirijevim fumaratom pri odraslih (glejte poglavji 4.8 Povzetek neželenih učinkov, prikazan v preglednici in 5.1).
The adverse reactions observed in paediatric subjects who received treatment with entecavir were consistent with those observed in clinical trials of entecavir in adults.(see a.
Pri pediatričnih bolnikih, ki so se zdravili z entekavirjem, so bili neželeni učinki skladni z neželenimi učinki, opaženimi v kliničnih preskušanjih entekavirja pri odraslih (glejte a.
The adverse reactions observed in patients treated for multiple myeloma are listed below by system organ class and frequency.
Neželeni učinki, ki so jih opazili pri bolnikih, zdravljenih zaradi diseminiranega plazmocitoma, so razvrščeni po organskem sistemu in pogostnosti.
The adverse reactions observed in patients treated for myelodysplastic syndromes and mantle cell lymphoma are listed below by system organ class and frequency.
Neželeni učinki, ki so jih opazili pri bolnikih, zdravljenih zaradi mielodisplastičnih sindromov in limfoma plaščnih celic, so navedeni spodaj po organskem sistemu in pogostnosti.
The adverse reactions observed with continued treatment for 384 weeks were consistent with the safety profile of tenofovir disoproxil fumarate.
Neželeni učinki, ki so jih opazili v 384-tedenskem neprekinjenem zdravljenju, so bili v skladu z varnostnim profilom dizoproksiltenofovirijevega fumarata.
The adverse reactions observed with Rasilez HCT or with monotherapy with one or both of the two components are included in the table below.
V spodnji preglednici so navedeni neželeni učinki, ki so jih opažali pri uporabi zdravila Rasilez HCT ali pri uporabi katere od obeh zdravilnih učinkovin v monoterapiji.
The adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment.
Neželeni učinki se večinoma pojavijo ob začetku zdravljenja in običajno izzvenijo v nekaj dneh nadaljnjega zdravljenja.
The adverse reactions presented have been identified from clinical studies as well as from post- marketing reports (an asterisk [*] indicates adverse reactions identified during post-marketing surveillance).
Predstavljeni neželeni učinki so bili opredeljeni v kliničnih študijah in poročilih iz obdobja trženja zdravila (zvezdica [*] pomeni neželene učinke, opredeljene med spremljanjem v obdobju trženja).
The adverse reactions presented in this section are based on the combined safety data of 62 RCC patients (see section 5.1) and 458 DTC patients (see Lenvima SmPC).
Neželeni učinki, opisani v tem poglavju, temeljijo na združenih varnostnih podatkih 62 bolnikov z RCC (glejte poglavje 5.1) in 458 bolnikov z DTC (glejte SmPC za zdravilo Lenvima).
The adverse reactions previously reported with one of the individual components of Rasilamlo (aliskiren and amlodipine) and included in the tabulated list of adverse reactions may occur with Rasilamlo.
Neželeni učinki, o katerih so predhodno poročali pri uporabi ene od posameznih učinkovin zdravila Rasilamlo (aliskiren in amlodipin) in so navedeni v tabelaričnem pregledu neželenih učinkov, se lahko pojavijo pri uporabi zdravila Rasilamlo.
The adverse reactions previously reported with one of the two active substances (aliskiren and hydrochlorothiazide) of Rasilez HCT and listed below may occur with Rasilez HCT.
Pri uporabi zdravila Rasilez HCT lahko pride do neželenih učinkov, ki so navedeni spodaj in o katerih so že poročali pri uporabi posamezne od obeh učinkovin v zdravilu Rasilez HCT (aliskirena in hidroklorotiazida).
The adverse reactions previously reported with one or both of the two active substances (aliskiren and amlodipine) of Rasilamlo and listed below may occur with Rasilamlo.
Pri uporabi zdravila Rasilamlo lahko pride do neželenih učinkov, ki so navedeni spodaj in o katerih so že poročali pri uporabi ene ali obeh posameznih učinkovin (aliskirena in amlodipina).
The adverse reactions profiles in the Multiple-Cycle extension of HEC and MEC studies for up to 6 additional cycles of chemotherapy were generally similar to those observed in Cycle 1.
Profili neželenih učinkov so bili v podaljšku HEC in MEC študij z več ciklusi zdravljenja (do 6 dodatnih ciklusov kemoterapije) na splošno podobni tistim po prvem ciklusu.
The adverse reactions reported below are based on pooled clinical trial data from phase II and III clinical trials involving 131 patients taking the medicinal product and on data from post-marketing surveillance.
Spodaj navedeni neželeni učinki, o katerih so poročali, temeljijo na zbranih podatkih iz kliničnih preskušanj II. in III. faze, v katere je bilo vključenih 131 bolnikov, ki so jemali zdravilo, in podatkih iz obdobja trženja.
The adverse reactions reported below are classified according to frequency of occurrence as follows:
Spodaj navedeni neželeni učinki so razvrščeni po pogostnosti na naslednji način:
The adverse reactions reported below are classified according to frequency of occurrence as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Poročani neželeni učinki so v nadaljevanju razvrščeni po pogostnosti, kot sledi: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000).
The adverse reactions reported by the highest percentage of patients were haematologic (anaemia, leukopaenia, neutropaenia, and thrombocytopaenia), metabolic (hypercholesterolaemia, hyperlipaemia, hyperglycaemia, increase of serum aspartate amino transferase (AST) and serum alanine aminotransferase (ALT) plasma levels), and digestive (mucositis, stomatitis, nausea, and vomiting).
Neželeni učinki, o katerih je poročal največji odstotek bolnikov, so bili hematološki (anemija, levkopenija, nevtropenija in trombocitopenija), presnovni (hiperholesterolemija, hiperlipidemija, hiperglikemija, povečanje ravni serumske aspartat aminotransferaze (AST) in serumske alanin aminotransferaze (ALT) v plazmi) in povezani s prebavo (mukozitis, stomatitis, navzea in bruhanje).
The adverse reactions reported by the investigator as at least possibly related to fondaparinux are presented within each frequency grouping (very common  1/10; common: 1/100 to < 1/10; uncommon:  1/1,000 to < 1/100; rare:  1/10,000 to <1/1,000; very rare <1/10,000) and system organ class by decreasing order of seriousness.
Neželeni učinki, o katerih so poročali raziskovalci in za katere je možna vsaj majhna povezava s fondaparinuksom, so navedeni v skupinah glede na pogostnost (zelo pogosti ≥ 1/10; pogosti ≥ 1/100 do < 1/10; občasni ≥ 1/1.000 do < 1/100; redki ≥ 1/10.000 do < 1/1.000; zelo redki < 1/10.000) in organski sistem v padajočem vrstnem redu po resnosti.
The adverse reactions reported by the investigator as at least possibly related to fondaparinux are presented within each frequency grouping (very common  1/10; common: 1/100 to < 1/10; uncommon:  1/1,000 to < 1/100; rare:  1/10,000 to <1/1,000; very rare <1/10,000) and system organ class by decreasing order of seriousness; these adverse reactions should be interpreted within the surgical and medical context.
Neželeni učinki, o katerih so poročali raziskovalci in za katere je možna vsaj majhna povezava s fondaparinuksom, so navedeni v skupinah glede na pogostnost (zelo pogosti ≥ 1/10; pogosti ≥ 1/100 do < 1/10; občasni ≥ 1/1.000 do < 1/100; redki ≥ 1/10.000 do < 1/1.000; zelo redki < 1/10.000) in organski sistem v padajočem vrstnem redu po resnosti; te neželene učinke moramo interpretirati v povezavi s kirurškim in internističnim posegom.
The adverse reactions reported by the investigator as at least possibly related to fondaparinux are presented within each frequency grouping (very common  1/10; common: 1/100 to < 1/10; uncommon:  1/1,000 to ≤ 1/100; rare:  1/10,000 to ≤1/1,000; very rare ≤1/10,000) and system organ class by decreasing order of seriousness.
Neželeni učinki, o katerih so poročali raziskovalci in za katere je možna vsaj majhna povezava s fondaparinuksom, so navedeni v skupinah glede na pogostnost (zelo pogosti  1/10; pogosti  1/100 do < 1/10; občasni  1/1.000 do < 1/100; redki  1/10.000 do < 1/1.000; zelo redki ≤ 1/10.000) in organski sistem v padajočem vrstnem redu po resnosti.